912947-38-7

Upstream product

• 32664-14-5 2-(4-bromophenyl)-4,4-dimethyl-2-oxazoline 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1622205-32-6 tert-butyl 4-(4-(ethoxycarbonyl)phenyl)-4-fluoropiperidine-1-carboxylate 
• 1622205-33-7 4-(1-(tert-butoxycarbonyl)-4-fluoropiperidin-4-yl)benzoic acid 
• 1622204-06-1 5-((2-(4-(4-fluoropiperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-methoxy-N-methyl-1H-indole-1-carboxamide 
• 1622205-99-5 C₂₁H₂₄FNO₂ 
• 1622206-00-1 C₁₄H₁₈FNO₂ 
• 912947-39-8 ethyl 4-(1-benzyl-4-hydroxypiperidin-4-yl)benzoate 

Relevant academic research and scientific papers

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.